Order Article Reprints

Ito S, Hirobe S, Kawakita T, Saito M, Quan Y-S, Kamiyama F, Ishii KJ, Nagao M, Fujisawa T, Tachibana M, et al. Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant. Pharmaceutics. 2020; 12(3):267. https://doi.org/10.3390/pharmaceutics12030267

Ito, Sayami, Sachiko Hirobe, Takuto Kawakita, Mio Saito, Ying-Shu Quan, Fumio Kamiyama, Ken J. Ishii, Mizuho Nagao, Takao Fujisawa, Masashi Tachibana, and et al. 2020. "Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant" Pharmaceutics 12, no. 3: 267. https://doi.org/10.3390/pharmaceutics12030267

Ito, S., Hirobe, S., Kawakita, T., Saito, M., Quan, Y.-S., Kamiyama, F., Ishii, K. J., Nagao, M., Fujisawa, T., Tachibana, M., & Okada, N. (2020). Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant. Pharmaceutics, 12(3), 267. https://doi.org/10.3390/pharmaceutics12030267